Patient and blood donor characteristics in relation to reduced folate carrier 80G>A polymorphism
| . | RFC GG variant . | RFC GA variant . | RFC AA variant . |
|---|---|---|---|
| Sex (fraction) | |||
| Male | 90 (0.3) | 136 (0.5) | 60 (0.2) |
| Female | 70 (0.3) | 106 (0.5) | 38 (0.2) |
| Median age, y (range) | 4.5 (1.1-14.8) | 4.5 (1.1-14.9) | 4.2 (1.6-14.6) |
| Phenotype; B/T lineage, no. (fraction) | 137 (0.3)/23 (0.4) | 206 (0.5)/36 (0.5) | 89 (0.2)/9 (0.1) |
| Risk; High/low, no. (fraction) | 45 (0.3)/115 (0.3) | 80 (0.5)/162 (0.5) | 25 (0.2)/73 (0.2) |
| Protocol; NOPHO-92/NOPHO-2000, no. (fraction) | 98 (0.3)/62 (0.3) | 131 (0.5)/111 (0.5) | 66 (0.2)/32 (0.2) |
| Chr21 copy no. higher than 2/2, no. (fraction) | 44 (0.4)/92 (0.3) | 55 (0.4)/152 (0.5) | 27 (0.2)/59 (0.2) |
| Relapse, CNS only/CNS plus other relapse involvements | 23 (0.3)-3 (0.3)/2 (0.4) | 39 (0.6)-7 (0.6)/3 (0.6) | 8 (0.1)-1 (0.1)/0 |
| Secondary malignancy, no. (fraction) | 1 (0.2) | 3 (0.6) | 1 (0.2) |
| Bone marrow transplantation, no. (fraction) | 6 (0.4) | 4 (0.2) | 6 (0.4) |
| Died in remission, no. (fraction) | 2 (0.7) | 1 (0.3) | 0 |
| t(12;21) in high/low risk, no. (fraction) | 3 (0.3)/19 (0.3) | 7 (0.6)/31 (0.5) | 2 (0.1)/14 (0.2) |
| Red cell transfusion, min (fraction)/max (range) | 51 (0.3)/56 (1-147) | 93 (0.5)/64 (1-324) | 35 (0.2)/64 (24-416) |
| Platelets transfusion, min (fraction)/max (range) | 38 (0.3)/41 (3-144) | 68 (0.5)/40 (2-216) | 25 (0.2)/64 (8-208) |
| Excluded patients with genotype, no. (fraction) | |||
| Death before first HDMTX | 3 (0.3) | 6 (0.5) | 2 (0.2) |
| Change of protocol before first HDMTX | 2 (0.4) | 2 (0.4) | 1 (0.2) |
| . | RFC GG variant . | RFC GA variant . | RFC AA variant . |
|---|---|---|---|
| Sex (fraction) | |||
| Male | 90 (0.3) | 136 (0.5) | 60 (0.2) |
| Female | 70 (0.3) | 106 (0.5) | 38 (0.2) |
| Median age, y (range) | 4.5 (1.1-14.8) | 4.5 (1.1-14.9) | 4.2 (1.6-14.6) |
| Phenotype; B/T lineage, no. (fraction) | 137 (0.3)/23 (0.4) | 206 (0.5)/36 (0.5) | 89 (0.2)/9 (0.1) |
| Risk; High/low, no. (fraction) | 45 (0.3)/115 (0.3) | 80 (0.5)/162 (0.5) | 25 (0.2)/73 (0.2) |
| Protocol; NOPHO-92/NOPHO-2000, no. (fraction) | 98 (0.3)/62 (0.3) | 131 (0.5)/111 (0.5) | 66 (0.2)/32 (0.2) |
| Chr21 copy no. higher than 2/2, no. (fraction) | 44 (0.4)/92 (0.3) | 55 (0.4)/152 (0.5) | 27 (0.2)/59 (0.2) |
| Relapse, CNS only/CNS plus other relapse involvements | 23 (0.3)-3 (0.3)/2 (0.4) | 39 (0.6)-7 (0.6)/3 (0.6) | 8 (0.1)-1 (0.1)/0 |
| Secondary malignancy, no. (fraction) | 1 (0.2) | 3 (0.6) | 1 (0.2) |
| Bone marrow transplantation, no. (fraction) | 6 (0.4) | 4 (0.2) | 6 (0.4) |
| Died in remission, no. (fraction) | 2 (0.7) | 1 (0.3) | 0 |
| t(12;21) in high/low risk, no. (fraction) | 3 (0.3)/19 (0.3) | 7 (0.6)/31 (0.5) | 2 (0.1)/14 (0.2) |
| Red cell transfusion, min (fraction)/max (range) | 51 (0.3)/56 (1-147) | 93 (0.5)/64 (1-324) | 35 (0.2)/64 (24-416) |
| Platelets transfusion, min (fraction)/max (range) | 38 (0.3)/41 (3-144) | 68 (0.5)/40 (2-216) | 25 (0.2)/64 (8-208) |
| Excluded patients with genotype, no. (fraction) | |||
| Death before first HDMTX | 3 (0.3) | 6 (0.5) | 2 (0.2) |
| Change of protocol before first HDMTX | 2 (0.4) | 2 (0.4) | 1 (0.2) |
There was no difference in the distribution of sex and genotype (P = .7). Among the healthy blood donors, there were 38 (0.36), 54 (0.51), and 14 (0.13) men in the RFC GG, GA, and AA variant groups, respectively, and 22 (0.23), 54 (0.56), and 20 (0.21) women, respectively.
NOPHO indicates Nordic Society of Pediatric Haematology and Oncology; CNS, central nervous system; and HDMTX, high-dose methotrexate.